T1	Treatment 19 45	gemcitabine plus docetaxel
T2	Treatment 53 80	capecitabine plus docetaxel
T3	Treatment 198 229	gemcitabine plus docetaxel (GD)
T4	Treatment 234 266	capecitabine plus docetaxel (CD)
T5	Treatment 354 384	monotherapy (GD→C or CD→G)
T6	Treatment 477 495	either gemcitabine
T7	Treatment 525 539	plus docetaxel
T8	Treatment 558 575	1 or capecitabine
T9	Treatment 609 628	1-14 plus docetaxel
T10	Treatment 674 704	received crossover monotherapy
T11	Treatment 1081 1085	More
T12	Treatment 1128 1132	than
T13	Treatment 1334 1343	comparing
T14	Treatment 1347 1350	and
T15	Treatment 1532 1539	groups.
T16	Treatment 1633 1645	neutropenia;
T17	Treatment 1723 1734	CONCLUSIONS
T18	Treatment 1738 1741	and
